News | Pharmaceuticals | February 07, 2017

GE Healthcare to Commercialize Rapiscan Agent Outside North America

Availability of Rapiscan worldwide will provide imaging for coronary artery disease in larger adult patient populations

GE Healthcare, Rapiscan stress imaging agent, North America, Rapidscan Pharma Solutions Inc.

February 7, 2017 — GE Healthcare’s Life Sciences business announced in January that it acquired Rapidscan Pharma Solutions Inc., which has the exclusive rights to produce and sell the pharmacological stress agent Rapiscan (regadenoson) in territories outside the U.S., Canada and Mexico. GE Healthcare will help bring improved access to Rapiscan, offering an alternative screening method for patients who are unable to undergo traditional cardiac stress imaging procedures.

Rapiscan is a European Medicines Agency (EMA)-approved selective coronary vasodilator, used as a pharmacological stress agent for radionuclide myocardial perfusion imaging (MPI) in adult patients. It is used in the diagnosis of coronary artery disease (CAD), the most common type of cardiovascular disease, accounting for over 680,000 deaths in Europe alone[1] .

While MPIs are most commonly performed after a patient has exercised, some patients at risk of CAD cannot exercise due to various conditions such as asthma and chronic obstructive pulmonary disease. Rapiscan reduces the risks[2] of MPI tests for these patients by stimulating a patient’s heart to bring on the effects of exercise.

GE Healthcare already distributes Rapiscan in the U.K. and Germany and will maintain existing supplier and distributor networks created by Rapidscan Pharma Solutions to expand its global reach. Its commercial rights will complement Astellas’ commercial distribution of regadenoson in the U.S., Canada, and Mexico.

For more information: www.gehealthcare.com

References

[1] European Society of Cardiology. European Cardiovascular Disease Statistics, 2012. https://www.escardio.org/static_file/Escardio/Press-media/press-releases/2013/EU-cardiovascular-disease-statistics-2012.pdf

[2] Cerqueira MD et al, on behalf of the ADVANCE MPI Trial Investigators. Effects of age, gender, obesity and diabetes on the efficacy and safety of the selective A2A agonist Rapiscan versus adenosine: integrated ADVANCE MPI trial results. J Am Coll Cardiol 2008; 1: 307-316.

[3] Rapidscan.Rapiscan: Information Memorandum. 2016; 4


Related Content

News | Cardiac Imaging

July 17, 2025— Heartflow, Inc. recently announced new data for its AI-enabled Heartflow Plaque Analysis, including final ...

Home July 17, 2025
Home
News | Cardiac Imaging

July 15, 2025 – Cleerly has announced that EviCore, a leading radiology benefit manager providing coverage guidelines to ...

Home July 16, 2025
Home
News | Cardiac Imaging

July 11, 2025 — Heartflow, Inc. has announced that its Heartflow Plaque Analysis will be included in updated cardiac ...

Home July 15, 2025
Home
News | Cardiac Imaging

July 9, 2025 — Cleerly, a leader in advanced cardiovascular imaging, will be presenting new research at the Society of ...

Home July 15, 2025
Home
News | Cardiac Imaging

Cleerly, a leader in cardiovascular imaging, today announced the promotions of two key executives to expanded leadership ...

Home July 02, 2025
Home
News | Cardiac Imaging

June 25, 2025 — Royal Philips and Methodist Hospitals recently announced the healthcare provider’s strategic investment ...

Home June 25, 2025
Home
News | Cardiac Imaging

June 12, 2025 — GE HealthCare has announced the combination of GE HealthCare’s proprietary features and algorithms with ...

Home June 12, 2025
Home
News | Cardiac Imaging

April 1, 2025 — UltraSight recently announced the presentation at the American College of Cardiology (ACC) Annual ...

Home April 15, 2025
Home
News | Cardiac Imaging

April 3, 2025 — Tower Health and Siemens Healthineers recently announced a 10-year agreement focused on equipment ...

Home April 04, 2025
Home
News | Cardiac Imaging

Pfizer has awarded $80,000 to Rutgers Robert Wood Johnson Medical School (RWJMS) to fund an Amyloidosis Fellowship at ...

Home December 19, 2024
Home
Subscribe Now